Tuberous Sclerosis Epidemiology Forecast 2025-2034

Tuberous sclerosis, also known as tuberous sclerosis complex, is characterized by the growth of benign tumors in various parts of the body, including the brain, lungs, kidneys, and skin, among others. The prevalence of tuberous sclerosis is estimated to be 1 case per 10,000 population. On the other hand, birth incidence is reported to be 1 case per 6000 population.

Tuberous Sclerosis Epidemiology Forecast Report Coverage

The “Tuberous Sclerosis Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of tuberous sclerosis. It projects the future incidence and prevalence rates of tuberous sclerosis across various populations. The study covers age and type as major determinants of the tuberous sclerosis-affected population. The report highlights patterns in the prevalence of tuberous sclerosis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of tuberous sclerosis in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Tuberous Sclerosis: Disease Overview

Tuberous sclerosis is a rare genetic disease that leads to the formation of non-cancerous tumors in the brain and other parts of the body, including the eyes, lungs, spinal cord, nerves, and skin, among others. The prognosis for the disease is highly variable and depends on the severity of the associated symptoms. Three types of brain tumors are seen in tuberous sclerosis: cortical tubers, subependymal nodules, and subependymal giant-cell astrocytomas.

Tuberous Sclerosis: Treatment Overview

There is no cure for tuberous sclerosis. However, treatment can help in managing symptoms. Anti-seizure drugs are often prescribed to treat seizures. Everolimus (Afinitor, Zortress) is also used for the treatment of certain types of kidney and brain growth that can’t be removed with a surgical procedure. Sirolimus (Hyftor) in the topical ointment form can be used for acne-like skin growths. Cryoablation, laser skin resurfacing, and skin grafts are some of the dermatology treatments for tuberous sclerosis-related skin symptoms.

Epidemiology

The tuberous sclerosis epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for tuberous sclerosis by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for tuberous sclerosis and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• Historically, the prevalence of tuberous sclerosis is estimated to be 1/10,000. However, recent data from the United Kingdom and Taiwan has reported prevalence at 1/20-25,000 and 1/100,000, respectively. Moreover, studies suggest that the current estimates are likely an underestimate.
• As per a study published in Pediatric Neurology (2021), the prevalence of tuberous sclerosis complex is estimated to be 1 case per 10,000 population whereas the birth incidence is reported to be 1 case per 6000 population.
• Various studies reveal that approximately 1 in 5000 people worldwide are affected by tuberous sclerosis complex.
• Tuberous sclerosis complex is reported to affect all races without an evident predominance. It affects both sexes equally and can be present at any age.

Country-wise Tuberous Sclerosis Epidemiology

The tuberous sclerosis epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of tuberous sclerosis varies significantly between countries owing to the differences in population genetics, availability and use of diagnostic tools, healthcare policies, and the level of awareness among clinicians regarding tuberous sclerosis symptoms, among others. In the United States, it is estimated that 1 in 6,000 children are born with tuberous sclerosis complex each year.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of tuberous sclerosis based on several factors.
• Tuberous Sclerosis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of tuberous sclerosis are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of tuberous sclerosis epidemiology in the 8 major markets?
• What will be the total number of patients with tuberous sclerosis across the 8 major markets during the forecast period?
• What was the country-wise prevalence of tuberous sclerosis in the 8 major markets in the historical period?
• Which country will have the highest number of tuberous sclerosis patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of tuberous sclerosis during the forecast period of 2025-2034?
• What are the currently available treatments for tuberous sclerosis?
• What are the disease risks, signs, symptoms, and unmet needs of tuberous sclerosis?

This product will be delivered within 3-5 business days.